Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
KD025
DRUG
2 trials
Sponsors
Kadmon Corporation, LLC
, Kadmon, a Sanofi Company
Conditions
Hepatic Impairment
Psoriasis Vulgaris
Phase 1
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
Completed
NCT04166942
Kadmon, a Sanofi Company
Hepatic Impairment
Start: 2019-12-11
End: 2022-06-06
Updated: 2022-07-18
Phase 2
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
Completed
NCT02317627
Kadmon Corporation, LLC
Psoriasis Vulgaris
Start: 2014-12-31
End: 2016-03-31
Updated: 2022-05-26
Related Papers
Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
Clinical and Translational Science
2025-07-01
Selective oral ROCK2 inhibitor reduces clinical scores in patients with Psoriasis Vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10 levels
The Journal of Immunology
2017-05-01
1 citations